AI-Based Mammography Software Receives FDA Clearance
By Medimaging International staff writers
05 Apr 2019
CureMetrix (La Jolla, CA, USA) has received clearance from the US Food and Drug Administration to market cmTriage, a workflow optimization tool that enables a radiologist to customize, sort, and prioritize their mammography worklist based on cases that may need immediate attention.
CureMetrix is a healthcare technology company that develops computer-aided detection (CAD) software based on artificial intelligence (AI) for medical image analysis. Instead of today’s method of first in, first out for reading through a screening mammography worklist, radiologists can now use CureMetrix cmTriage to identify which cases are suspicious and focus on those first. They can also use cmTriage to optimize their clinical workflow by sending the suspicious cases to their most senior radiologists or reading the suspicious cases immediately before the patient has even left the clinic. CureMetrix cmTriage has an area under the curve (AUC) of 0.95. With this high level of efficacy, radiologists can expect cmTriage to highlight the suspicious cases without excessive false positives.
“Early and accurate detection in breast cancer is key in improving cancer survival rates worldwide through the development of next generation medical image analysis solutions. With 40 million mammograms a year in the US, only five cancers per 1,000 are being found at screening. cmTriage allows the radiologist to prioritize their worklist, creating the potential to help doctors move more quickly through their reviews and find those cancers by highlighting the suspicious cases. “Our ability to bring cmTriage to the medical community is a major milestone in our mission to deliver CAD that Works to support the radiologist and the patients they serve,” said Kevin Harris, CEO and Board Director for CureMetrix.
“Our goal is to provide radiologists with analytic tools to enhance diagnosis in breast cancer screening and augment treatment decisions,” said Lisa Watanabe, M.D., Chief Medical Officer at CureMetrix and Clinical Associate Professor at University of Southern California. “On average, early signs of breast cancer may be missed up to 50% of the time on mammograms. Analysis of mammograms with cmTriage has the potential to help radiologists focus on the suspicious cases and increase their productivity. This will allow for more time to engage with our patients and the healthcare team. Providing radiologists with the most advanced technology and tools like cmTriage to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs and increased assurance that patients are receiving high quality and accurate clinical care.”